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Abstract
!
Peroxisome proliferator-activated receptor γ
plays an important role in lipid and glucose ho-
meostasis and is the target of many drug discov-
ery investigations because of its role in diseases
such as type 2 diabetes. Activation of peroxisome
proliferator-activated receptor γ by agonists leads
to a conformational change in the ligand-binding
domain altering the transcription of several target
genes involved in glucose and lipid metabolism,
resulting in, for example, facilitation of glucose
and lipid uptake and amelioration of insulin resis-
tance, and other effects that are important in the
treatment of type 2 diabetes. Peroxisome prolife-
rator-activated receptor γ partial agonists are
compounds with diminished agonist efficacy
compared to full agonists; however, they main-
tain the antidiabetic effect of full agonists but do
not induce the same magnitude of side effects.
This mini-review gives a short introduction to in
silico screening methods and recent research ad-
vances using computational approaches to identi-
fy peroxisome proliferator-activated receptor γ
agonists, especially partial agonists, from natural
sources and how these ligands bind to the per-
oxisome proliferator-activated receptor γ in order
to better understand their biological effects.
Abbreviations
!
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l.Introduction
!
Natural products have been and continue to be
rich sources for drug discovery. Today over 60%
of the drugs that are on the market derive from
natural sources [1,2]. Peroxisome proliferator-ac-
tivated receptor γ (PPARγ) plays an essential role
in lipid and glucose homeostasis and is the target
for many drug discovery efforts because of its role
in diseases, such as T2D [3–5]. Obesity-linked
phosphorylation of PPARγ by the protein kinase
Cdk5 seems to be involved in the pathogenesis of
insulin resistance, and thus the development of
T2D. Blocking the phosphorylation by PPARγ lig-
ands (agonists) can restore a more normal non-
diabetic pattern of gene expression [6]. The TZDs,
a class of synthetic insulin-sensitizing drugs, tar-
get and activate PPARγ. Activation of PPARγ byRγ… Planta Med 2015; 81: 488–494agonists, such as TZDs, leads to a conformational
change in the LBD altering the transcription of
several target genes involved in glucose and lipid
metabolism, resulting in, for example, the facilita-
tion of glucose and lipid uptake, stimulation of
glucose oxidation, a decrease in free fatty acid lev-
els, and the amelioration of insulin resistance [3–
5]. Administration of TZDs can cause severe side
effects, which have been linked to their behavior
as full agonists of PPARγ [7]. PPARγ partial ago-
nists are compounds with diminished agonist ef-
ficacy that maintain the antidiabetic effect of full
agonists but usually do not induce the same mag-
nitude of side effects [8]. The different pharma-
cology properties of full and partial agonists indi-
cate that changes in the ligand-receptor inter-
action are responsible for these differences.
Table 1 The most important programs and algorithms used for docking.
Program Algorithm Ref.
AutoDock Lamarckian Genetic Algorithm [64]
DOCK Volume- or shape-based algorithm [65]
FlexX Incremental ligand fragmentation and
reconstruction
[66]
Glide Systematic search [67]
GOLD Genetic algorithm [68]
LigandFit Monte Carlo approaches [69]
ParaDOCKs Particle swarm optimization and other
metaheuristics
[70]
Surflex Surface-basedmolecular similarity methods [71]
489Mini ReviewsAwide variety of promising PPARγ partial agonists of plant origin
have been identified using a bioassay-guided approach. Bioassay-
guided fractionation is a very efficient method for the discovery
of natural products with interesting bioactivities from natural
sources, but it is a tedious process involving time-consuming se-
paration steps combined with biological test models in vitro and/
or in vivo. In recent years, the field of computational techniques
has been evolving towards applying in silico VS to support the re-
search in drug discovery, design, development, and optimization
[9–11].
In silico screening has been established as one of the most impor-
tant computational techniques used for prioritizing compounds
to be selected for experimental testing. This mini-review gives a
short introduction to in silico screening methods and provides an
assessment of the current state-of-the-art computational ap-
proaches to identify PPARγ agonists, especially partial agonists,
from natural sources and discusses how these ligands can bind
to PPARγ in order to better understand their biological effects.: U
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l.The Complexity of Natural Products with Respect to
Molecular Modelling
!
Natural products have several advantages, but also challenges,
when viewed from the perspective of a medicinal chemist. Un-
doubtedly, they show high diversity, bioavailability, and contain
bio-privileged structures [12]. However, to work with natural
products in biochemical assays, they have to be isolated from
multicomponent mixtures using complex separation procedures
requiring expertise in phytochemistry and analytical chemistry.
Furthermore, natural products show higher chemical complexity
than classical ”drug-like”molecules, including higher flexibility, a
higher number of ketones and hydroxyl groups, and often a large
number of chiral centers [13,14]. This complexity results in fur-
ther challenges for computational chemistry and in silico VS, es-
pecially in terms of handling stereochemistry in the correct way
and in covering conformational space when dealing with highly
flexible molecules.D
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byComputer-assisted Drug Design and Virtual Screening
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In order to deal with the high experimental effort in isolating and
testing natural products, in silico VS methods have become a suc-
cessful technique to enhance experimental success rates by pri-
oritizing those natural products that show a high probability to
bind to a specific target. Plant extracts containing several poten-
tial bioactive natural products can thus be prioritized for testing
according to computational predictions for each contained con-
stituent. Subsequent separation is only performed if the extract
shows biological activity and the high efforts of separation [15]
can be guided by the hypotheses generated in silico [16].
Several computer-aided methods exist for VS, which can roughly
be divided into structure- and ligand-based methods. Structure-
based modelling relies on the availability of an experimentally
determined structure of the macromolecular target under inves-
tigation. The Protein Data Bank (PDB) [17,18] represents the larg-
est public repository of protein and nucleic acid structures deter-
mined by X‑ray crystallography or NMR and currently comprise
more than a hundred thousand macromolecular structures,
many of themwith co-crystallized ligands.The most popular structure-based approaches are docking and
structure-based 3D pharmacophores. While docking flexibly fits
a ligand into a protein-binding site [19–22], structure-based
3D pharmacophores describe protein-ligand interactions by an
ensemble of chemical features that can then be used for VS [23].
When employed for the VS of large molecule databases, docking
suffers from a high false positive rate, which is mainly caused by
problems in scoring [24–26]. Nevertheless, docking remains the
method of choice when investigating a binding mode and gene-
rating ideas for further lead optimization [27]. The most impor-
tant docking methods are summarized in l" Table 1. Structure-
based 3D pharmacophores can be optimized to contain those
chemical features that are known to be important for binding
and can thus, if developed carefully, represent predictive VS fil-
ters [28].
Despite recent advances in protein crystallization, especially with
respect to membrane-bound proteins [29], not all relevant mac-
romolecular targets [30] can be crystallized. In those cases, lig-
and-based methods are used to overcome this limitation. Based
on the hypothesis that different ligands bind at the pocket in a
similar manner, a similarity search with respect to known active
compounds can be performed. In case of a ligand-based pharma-
cophore, common chemical features are derived using a 3D over-
lay [31]. More simple approaches use steric similarity to the most
active ligand to perform VS [26,32].
However, further research into lesser-understood biochemical
processes is necessary to improve the reliability of VS as a stand-
alone process for identifying bioactive constituents. These pro-
cesses include protein flexibility and induced-fit adaptations,
the role of water in solvation, desolvation, and ligand binding,
the involvement of electrostatics, as well as the stereochemistry
and conformational space of the ligands [18,33]. Another factor
that can limit VS productivity is the amount of information avail-
able when building a compound library. Although a huge amount
of information is available when considering natural products for
the treatment and prevention of diseases, they do not include all
potential bioactive natural products. Finally, VS also has its limi-
tation when considering the concentration needed for a ligand to
elicit its therapeutic effect. Docking predicts ligands that may
elicit the desired activity, but bioassays are needed to further re-
fine the group of viable candidates to a selected group of hits that
at a specific concentration will activate the protein, e.g., PPARγ.
However, as mentioned in the introduction and in the beginning
of this section, VS can be useful after the fractionation of extracts
and structural elucidation of major components in the fractions
to aid in identifying which constituents are potential bioactive
compounds, such as PPARγ partial agonists.El-Houri RB et al. Identification of PPARγ… Planta Med 2015; 81: 488–494
Fig. 1 3D structure of PPARγ. The crystal structure of PPARγ (PDB code:
2F4B [72]) is shown with α-helices colored in red, β-sheets in yellow, and
the ligand-binding site in grey. (Color figure available online only.)
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l.Peroxisome Proliferator-Activated Receptor γ
As a Target Protein
!
PPARγ exist as two isoforms, PPARγ1 and PPARγ2, which are ex-
pressed in many tissues. In humans, both PPARγ1 and γ2 are
abundant in adipose tissue but are, for example, present at low
levels in skeletal muscle [34]. In order to understand the binding
mode of ligands toward PPARγ, currently, 124 crystal structures
of PPARγ LBD are available of which 109 contain co-crystallized
ligands [17]. The binding mode of partial agonists to PPARγ has
been intensively studied revealing different binding modes,
which allowed for a more detailed investigation and subsequent
identification of potent PPARγ partial agonists [35–38].
Investigation of several known crystallographic structures of the
PPARγ LBD bound to an agonist revealed two binding modes in
the same LBD, which correspond to full and partial agonists [39].
The LBP of the PPARγ LBD is a large Y-shaped ligand-binding cav-
ity, consisting of an entrance (arm III) that branches off into two
binding pockets (arm I and arm II). Arm I is extended toward he-
lix H12 (H12) and arm II is situated between helix H3 (H3) and
the β-sheet (l" Fig. 1). Arm I is the only substantially polar cavity
of the PPARγ LBD, whereas arm II and the interior of arm III are
mainly hydrophobic [40]. Full agonists occupy arm I forming a
network of hydrogen bonds with the side chains of amino acids
Ser289, His323, His449, and Tyr473. These interactions stabilize
H12 and are mainly responsible for the transactivation activity
of PPARγ. In addition, full agonists also occupy arm II through a
hydrophobic tail [41,42]. On the other hand, the partial agonists
interact mainly with amino residues on regions other than H12
through a hydrogen bond with Ser342 of arm III, but also with
arm II through several hydrophobic contacts [35,36]. This bind-
ing mode causes a lower degree of H12 stabilization and an in-
crease in the stabilization of H3 that affects the recruitment of co-
activators and decreases the transactivation activity of PPARγ [43,
44].
Although co-crystal structures of the PPARγ LBD bound to ligands
give information on atomic differences in the LBD, it provides lit-
tle insight into the graded activity of the ligands and therefore
does not explain why agonists with different PPARγ transactiva-
tion activities show similar insulin-sensitizing potencies. How-
ever, recent studies have demonstrated that the antidiabetic effi-
cacy of different ligands correlates with the ligand-binding affin-
ity as well as their ability to inhibit phosphorylation of PPARγ by
Cdk5 at Ser273 in PPARγ2 and Ser245 in PPARγ1, thereby pre-
venting the unregulated expression of some target genes in-
volved in lipid and glucose homeostasis [6,45,46]. Furthermore,
the potency of blockage of Ser273/Ser245 phosphorylation by lig-
ands appears to be associated with the strength of interaction
with the backbone amide at Ser342 (graded PPARγ agonism) and
seems not to depend on the degree of classical agonist action of
full agonists by stabilizing H12 [45,46]. A substantial part of the
antidiabetic effect of full and partial agonists of PPARγmay there-
fore be explained by the inhibition of PPARγ phosphorylation.
The side effects of full agonists are therefore likely to occur
through the classical agonist action. Thus, an effective partial ag-
onist of PPARγwith reduced side effects should then have a weak
transactivation activity, but a high phosphorylation inhibitory
activity on PPARγ at Ser273/Ser245 [45,46]. Finally, Hughes et al.
[47] have recently demonstrated that synthetic ligands designed
to mimic the activity of endogenous ligands (fatty acid deriva-
tives) via binding to the canonical hydrophobic LBP of the PPARγ
LBD are able to bind to an alternate site on the LBD. Alternate siteEl-Houri RB et al. Identification of PPARγ… Planta Med 2015; 81: 488–494binding affects the structure and function of PPARγ, and hence
may contribute to the pharmacological response of PPARγ lig-
ands. Alternate site binding can occur via the following three
mechanisms of potential pharmacological relevance [47]: (1)
binding of two molecules of the same ligand to PPARγ, one to
the canonical LBP and a second to the alternate binding site; (2)
the canonical LBP is ”blocked” by a covalently bound irreversible
antagonist; and (3) the canonical LBP is covalently bound to an
endogenous ligand. If, for example, the PPARγ LBD is occupied by
a covalently bound endogenous ligand, such as a prostaglandin
(e.g., 15-deoxy-Δ12,14-prostaglandin J2) or an oxidized fatty acid
(e.g., 5-oxoeicosatetraenoic acid) [48,49], as described in the lat-
ter mechanism, the alternate binding site could be a target for al-
losteric modulators [47].
The above-mentioned new findings have not yet been applied in-
to in silico VS, but constitute very useful information for under-
standing the mechanism of ligand and receptor dynamics and
thus the mechanism of action of full and partial agonists of
PPARγ. Finally, incorporation of this new knowledge in VS may
be a stepping-stone for the identification of new and more effi-
cient ligands for PPARγ.Peroxisome Proliferator-Activated Receptor γ Agonists
From Natural Sources Discovered by Virtual Screening
!
Considering that plants have a long history in the traditional
treatment of diabetes [50], natural product libraries represent a
very promising source of novel PPARγ ligands. Natural sources
that contain PPARγ agonists have been described in a few reviews
[51–53]. Although these reviews do not represent an exhaustive
and updated source of information about natural sources for
Fig. 2 Chemical structures of naturally occurring flavonoids (apigenin,
chrysin, naringenin, hesperidin) and isoflavonoids (pseudobaptigenin, bio-
chanin A, genistein) discovered by virtual screening as PPARγ agonists.
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l.PPARγ agonists, they contain useful information that may be
helpful in building up natural product libraries to be used in VS.
To date, several VS studies have been used successfully to identify
PPARγ agonists, including partial agonists from botanical sources.
The first VS of a natural product library to identify novel PPARγ
agonists was performed by Salam et al. [54]. They used a struc-
ture-based docking method and screened an in-house natural
product library consisting of 200 compounds extracted from bo-
tanical sources. The compounds were examined for their poten-
tial to engage several residues in a binding mode typical for
PPARγ agonists [40–42]. Their screening resulted in identifying
several flavonoids, isoflavonoids, gingeroids, and ginkolides as
potential PPARγ full agonists, with flavonoids/isoflavonoids being
the most promising. Flavonoids/isoflavonoids of particular inter-
est were apigenin, chrysin, pseudobaptigenin, biochanin A, ge-
nistein, and hesperidin (l" Fig. 2). When tested in vitro for cell-
based transcriptional factor activity, all compounds demonstrat-
ed significant activation of PPARγ. The above screening also se-
lected the flavanone naringenin (l" Fig. 2) among the best scoring
docked compounds, which was later confirmed to activate PPARγ
in vitro by Christensen et al. [55].
Using a structure-based pharmacophore screening of the Analy-
tiCon Discovery collection (Analyticon Discovery GmbH) of natu-
ral products and derivatives, Tanrikulu et al. [56] were able to
identify two semisynthetic derivatives of the sesquiterpene lac-
tone α-santonin (α-santonin-derivative 1 and α-santonin-deriva-
tive 2; l" Fig. 3) as potential PPARγ agonists. The testing of these
compounds in a cellular reporter gene assay revealed that α-san-
tonin-derivative 1 activated PPARγ with 110% relatively to the
PPARγ full agonist pioglitazone while it activated PPARα with
16% relatively to the PPARα agonist GW7647. This indicates that
this compound acts as a PPARα/γ dual agonist. In comparison, α-
santonin-derivative 2 only activated PPARγwith 33% relatively to
pioglitazone without activation of PPARα, indicating that this
compound is a selective PPARγ partial agonist. Docking of α-san-
tonin-derivative 1 into a PPARγ structure supported its function
as a PPARγ full agonist as it formed hydrogen bonds to several
residues, including Tyr473 [40–42].
In aiming to identify PPARγ partial agonists, several studies have
been performed using pharmacophore-based VS on different
natural product libraries (DIOS database [57], Chinese Herbal
Medicine database [58], Chinese Herbal Constituents database
[59], Natural product subset of the ZINC database [60], and in-
house natural products databases). Fakhrudin et al. [58] identi-
fied three neolignans (dieugenol, tetrahydrodieugenol, and mag-
nolol; l" Fig. 4) as PPARγ partial agonists. The results were also
confirmed by a PPARγ luciferase reporter gene transactivation as-
say, as the maximal fold activation by all three compounds was
several folds lower than the full agonist pioglitazone. The three
compounds were docked into the X‑ray structure of PPARγ. X‑ray
crystallography experiments later confirmed the computational-
ly predicted bivalent binding (l" Fig. 5) and a conformation typi-
cal for partial agonists, including a hydrogen bond to the residue
Ser342 [35,36]. Petersen et al. [61] identified oleanolic acid
(l" Fig. 4), which also shows a binding mode different from full
agonists.
Lately, Guasch et al. [62,63] performed a VS study to identify po-
tential PPARγ partial agonists in extracts with known antidiabetic
activity. They developed a structure-based pharmacophore and
anti-pharmacophore (i.e., a 3D interaction pattern that matches
those molecules, which describes the binding to undesired PPARγ
isoforms or binding modes) to identify potential PPARγ partialagonists. The anti-pharmacophore was used to exclude possible
full agonists because they present more clearly defined features
than partial agonists. They applied their VS workflow to a group
of PPARγ partial agonists known from the literature and some de-
coys. Sixty-five compounds were predicted by the VS workflow
to be potential PPARγ partial agonists and have all been isolated
from 74 natural sources. Among the identified compounds, some
were found in extracts that exert antidiabetic activities while
others were related to extracts never recorded for antidiabetic
activity.
In silico screening has thus proven to be a highly effective en-
hancement to bioassay screening and thus renders the search
for novel potential antidiabetic plant extracts and compounds
faster and cheaper than the usual bioassay-guided approach.Conflict of Interest
!
The authors declare no conflict of interest.El-Houri RB et al. Identification of PPARγ… Planta Med 2015; 81: 488–494
Fig. 3 Chemical structures of pioglitazone,
GW7647, α-santonin-derivative 1, and α-santonin-
derivative 2. Pioglitazone has one chiral center situ-
ated in the thiazolidinedione ring and the active
substance is an equimolar mixture of the (R)- and
(S)-enantiomers of pioglitazone (racemic mixture)
[73].
Fig. 4 Chemical structures of neolignans (dieugenol, tetrahydrodieuge-
nol, magnolol) and the triterpenoid oleanolic acid isolated from natural
sources and discovered by in silico screening as being potential PPARγ par-
tial agonists.
Fig. 5 Binding mode of magnolol to PPARγ. Two magnolol molecules
bound to the ligand-binding site of PPARγ are shown in ball and stick de-
piction (PDB code 3R5N [74]). Key interacting residues are shown in stick
mode. (Color figure available online only.)
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